

Mark Andrew Ainsworth

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4740859/publications.pdf>

Version: 2024-02-01

84
papers

3,444
citations

186265
28
h-index

138484
58
g-index

90
all docs

90
docs citations

90
times ranked

3425
citing authors

#	ARTICLE	IF	CITATIONS
1	A systematic monitoring approach to biologic therapies in inflammatory bowel disease: patientsâ€™ and physiciansâ€™ preferences and adherence. <i>Scandinavian Journal of Gastroenterology</i> , 2022, 57, 274-281.	1.5	4
2	Fatigue is a systemic extraintestinal disease manifestation largely independent of disease activity, chronicity, and nutritional deficiencies in inflammatory bowel disease on biologics. <i>Scandinavian Journal of Gastroenterology</i> , 2022, , 1-7.	1.5	4
3	Discontinuation of Infliximab Therapy in Patients with Crohnâ€™s Disease. , 2022, 1, .		17
4	Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease. <i>United European Gastroenterology Journal</i> , 2021, 9, 91-101.	3.8	14
5	Drug Levels Associated with Optimal Discrimination Between Remission and Non-Remission and Comparison of Antibody Assays During First Year of Stable Infliximab Maintenance Therapy in Inflammatory Bowel Disease. <i>Therapeutic Drug Monitoring</i> , 2021, Publish Ahead of Print, .	2.0	1
6	Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 884-890.	1.5	11
7	Treatment to target in patients with inflammatory bowel disease. What is the evidence?. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 528-536.	1.5	4
8	Challenges and opportunities for IBD drug development: from early stage to regulatory approval. <i>Gut</i> , 2020, 69, 1157-1161.	12.1	8
9	Progressionâ€™free survival (PFS) in oncology: caveat emptor!. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2019, 124, 237-238.	2.5	2
10	Methotrexate for inflammatory bowel disease: time for reconsideration. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 407-409.	3.0	6
11	Absence of Relationship Between Crohn's Disease Activity Index or C-Reactive Protein and Infliximab Exposure Calls for Objective Crohn's Disease Activity Measures for the Evaluation of Treatment Effects at Treatment Failure. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 235-242.	2.0	4
12	Biosimilars for Management of Crohn Disease. <i>Annals of Internal Medicine</i> , 2019, 170, 129.	3.9	3
13	A Role for Thiopurine Metabolites in the Synergism Between Thiopurines and Infliximab in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 298-305.	1.3	23
14	Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1583-1591.	2.3	8
15	Inflammatory bowel disease with primary sclerosing cholangitis: A Danish populationâ€™based cohort study 1977â€™2011. <i>Liver International</i> , 2018, 38, 532-541.	3.9	58
16	Outcome of continued infliximab therapy in Crohnâ€™s disease patients with response but without remission after one year of infliximab â€™ a retrospective cohort study. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 930-937.	1.5	3
17	Outcomes After Primary Infliximab Treatment Failure in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1210-1217.	1.9	21
18	Magnitude of Increased Infliximab Clearance Imposed by Anti-infliximab Antibodies in Crohnâ€™s Disease Is Determined by Their Concentration. <i>AAPS Journal</i> , 2017, 19, 223-233.	4.4	25

#	ARTICLE	IF	CITATIONS
19	Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease. <i>BMC Medicine</i> , 2017, 15, 184.	5.5	34
20	Monitoring immunogenicity of protein-based TNF antagonists. <i>Frontline Gastroenterology</i> , 2016, 7, 152-154.	1.8	2
21	Time Course and Clinical Implications of Development of Antibodies Against Adalimumab in Patients With Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 483-489.	2.2	18
22	Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1999-2015.	1.9	82
23	Mo1893 Long-Term Outcomes After Primary Infliximab Treatment Failure in Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2016, 150, S809.	1.3	0
24	Circulating Cytokines and Cytokine Receptors in Infliximab Treatment Failure Due to TNF-Î± Independent Crohn Disease. <i>Medicine (United States)</i> , 2016, 95, e3417.	1.0	19
25	Will novel oral formulations change the management of inflammatory bowel disease?. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 709-718.	4.1	23
26	Management of Iron-Deficiency Anemia in Inflammatory Bowel Disease. <i>Medicine (United States)</i> , 2015, 94, e963.	1.0	67
27	Implications of Infliximab Treatment Failure and Influence of Personalized Treatment on Patient-reported Health-related Quality of Life and Productivity Outcomes in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 1032-1042.	1.3	16
28	Authors' response: Importance of defining loss of response before therapeutic drug monitoring. <i>Gut</i> , 2015, 64, 1340-1341.	12.1	6
29	Changes in Serum Trough Levels of Infliximab During Treatment Intensification but not in Anti-infliximab Antibody Detection are Associated with Clinical Outcomes after Therapeutic Failure in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 238-245.	1.3	56
30	Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn's Disease Patients Failing Infliximab. <i>Digestive Diseases and Sciences</i> , 2015, 60, 2762-2770.	2.3	73
31	Systematic Information to Health-Care Professionals about Vaccination Guidelines Improves Adherence in Patients With Inflammatory Bowel Disease in Anti-TNF Therapy. <i>American Journal of Gastroenterology</i> , 2015, 110, 1526-1532.	0.4	20
32	Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial. <i>BMJ Open</i> , 2014, 4, e005887.	1.9	11
33	Antibodies Against Infliximab Are Associated with De Novo Development of Antibodies to Adalimumab and Therapeutic Failure in Infliximab-to-Adalimumab Switchers with IBD. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 1714-1721.	1.9	90
34	P536 Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S291.	1.3	1
35	Clinical Implications of Measuring Drug and Anti-Drug Antibodies by Different Assays When Optimizing Infliximab Treatment Failure in Crohn's Disease: Post Hoc Analysis of a Randomized Controlled Trial. <i>American Journal of Gastroenterology</i> , 2014, 109, 1055-1064.	0.4	125
36	Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. <i>Gut</i> , 2014, 63, 919-927.	12.1	413

#	ARTICLE	IF	CITATIONS
37	P300 Vaccination routines during anti-TNF treatment in IBD: Do patients adhere to ECCO's guidelines? Journal of Crohn's and Colitis, 2014, 8, S189.	1.3	1
38	P558 Antibodies against infliximab are associated with increased risk of anti-adalimumab antibody development in patients with inflammatory bowel disease. Journal of Crohn's and Colitis, 2014, 8, S300.	1.3	0
39	Which Biological Agents Are Most Appropriate for Ulcerative Colitis?. Annals of Internal Medicine, 2014, 160, 733.	3.9	6
40	Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease. New England Journal of Medicine, 2013, 369, 754-762.	27.0	282
41	Comparison of Techniques for Monitoring Infliximab and Antibodies Against Infliximab in Crohn's Disease. Therapeutic Drug Monitoring, 2013, 35, 530-538.	2.0	104
42	Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease. Alimentary Pharmacology and Therapeutics, 2012, 36, 650-659.	3.7	45
43	Biological Treatment of Crohn's Disease. Digestive Diseases, 2012, 30, 121-133.	1.9	9
44	Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease. Journal of Crohn's and Colitis, 2012, 6, 108-111.	1.3	62
45	Therapeutic infliximab drug level in a child born to a woman with ulcerative colitis treated until gestation week 31. Journal of Crohn's and Colitis, 2012, 6, 358-361.	1.3	26
46	Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study. Scandinavian Journal of Gastroenterology, 2012, 47, 518-527.	1.5	89
47	Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease. Inflammatory Bowel Diseases, 2012, 18, 2209-2217.	1.9	90
48	Comparison of Techniques for Monitoring Infliximab and Antibodies to Infliximab in Crohn's Disease Patients with Infliximab Treatment Failure. American Journal of Gastroenterology, 2012, 107, S622.	0.4	0
49	Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scandinavian Journal of Gastroenterology, 2011, 46, 310-318.	1.5	171
50	Can Measurements of Anti-Infliximab Antibodies Predict Acute Severe Infusion Reactions to Infliximab?. Gastroenterology, 2011, 140, S-774.	1.3	4
51	Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2011, 34, 51-58.	3.7	135
52	Incidence of acute severe infusion reactions to infliximab depends on definition used rather than assay: authors' reply. Alimentary Pharmacology and Therapeutics, 2011, 34, 404-405.	3.7	5
53	Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNF α antagonists. Journal of Immunological Methods, 2011, 373, 229-239.	1.4	91
54	Comment on 'Predicting the response to infliximab from trough serum levels'. Gut, 2010, 59, 1298-1299.	12.1	1

#	ARTICLE	IF	CITATIONS
55	Long-term effects and colectomy rates in ulcerative colitis patients treated with infliximab: A Danish single center experience. <i>Scandinavian Journal of Gastroenterology</i> , 2010, 45, 1457-1463.	1.5	28
56	Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. <i>Scandinavian Journal of Gastroenterology</i> , 2009, 44, 774-781.	1.5	134
57	Tumor Necrosis Factor-Alpha Binding Capacity and Anti-Infliximab Antibodies Measured by Fluid-Phase Radioimmunoassays as Predictors of Clinical Efficacy of Infliximab in Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2008, 103, 944-948.	0.4	147
58	Systematic review: coxibs, non-steroidal anti-inflammatory drugs or no cyclooxygenase inhibitors in gastroenterological high-risk patients?. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 27-33.	3.7	29
59	Effect of Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide on Pancreatic, Hepatic and Duodenal Mucosal Bicarbonate Secretion in the Pig. <i>Digestion</i> , 2003, 67, 56-66.	2.3	21
60	The cystic fibrosis transmembrane conductance regulator is not a base transporter in isolated duodenal epithelial cells. <i>Acta Physiologica Scandinavica</i> , 2002, 174, 327-336.	2.2	9
61	Molecular and functional evidence for electrogenic and electroneutral Na ⁺ -HCO ₃ ⁻ cotransporters in murine duodenum. <i>American Journal of Physiology - Renal Physiology</i> , 2001, 280, G332-G343.	3.4	57
62	NHE1, NHE2, and NHE3 contribute to regulation of intracellular pH in murine duodenal epithelial cells. <i>American Journal of Physiology - Renal Physiology</i> , 2000, 278, G197-G206.	3.4	48
63	Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor- α in ulcerative colitis. <i>American Journal of Gastroenterology</i> , 1999, 94, 2923-2928.	0.4	74
64	Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin in ulcerative colitis. <i>Gastroenterology</i> , 1998, 114, A1051.	1.3	0
65	Acid/Base Transporters in Human Duodenal Enterocytes. <i>Scandinavian Journal of Gastroenterology</i> , 1998, 33, 1039-1046.	1.5	15
66	Acid-stimulated duodenal bicarbonate secretion involves a CFTR-mediated transport pathway in mice. <i>Gastroenterology</i> , 1997, 113, 533-541.	1.3	95
67	CFTR mediates cAMP- and Ca ²⁺ -activated duodenal epithelial HCO ₃ ⁻ secretion. <i>American Journal of Physiology - Renal Physiology</i> , 1997, 272, G872-G878.	3.4	66
68	Cyclic Adenosine-3',5'-Monophosphate Production Is Greater in Rabbit Duodenal Crypt Than in Villus Cells. <i>Scandinavian Journal of Gastroenterology</i> , 1996, 31, 233-239.	1.5	14
69	Acid-Base Transport in Isolated Rabbit Duodenal Villus and Crypt Cells. <i>Scandinavian Journal of Gastroenterology</i> , 1996, 31, 1069-1077.	1.5	19
70	Higher proximal duodenal mucosal bicarbonate secretion is independent of Brunner's glands in rats and rabbits. <i>Gastroenterology</i> , 1995, 109, 1160-1166.	1.3	18
71	The role of nutrient chloride on mammalian duodenal mucosal bicarbonate secretion. <i>Gastroenterology</i> , 1995, 108, A339.	1.3	0
72	Duodenal Mucosal Bicarbonate Secretion in Pigs Is Accompanied by Compensatory Changes in Pancreatic and Biliary HCO ₃ ⁻ Secretion. <i>Scandinavian Journal of Gastroenterology</i> , 1994, 29, 889-896.	1.5	5

#	ARTICLE	IF	CITATIONS
73	The Effect of Gastrin-Releasing Peptide on Porcine Pancreaticobiliary Bicarbonate Secretion Is mediated by secretin. <i>Scandinavian Journal of Gastroenterology</i> , 1994, 29, 195-202.	1.5	16
74	Review article: gastroduodenal bicarbonate secretion. <i>Alimentary Pharmacology and Therapeutics</i> , 1994, 8, 475-488.	3.7	79
75	Effect of Stimulation of Mucosal HCO ₃ ⁻ Secretion on Acid-Induced Injury to Porcine Duodenal Mucosa. <i>Scandinavian Journal of Gastroenterology</i> , 1993, 28, 1091-1097.	1.5	14
76	Cigarette Smoking Inhibits Acid-Stimulated Duodenal Mucosal Bicarbonate Secretion. <i>Annals of Internal Medicine</i> , 1993, 119, 882.	3.9	27
77	Relative Importance of Pancreatic, Hepatic, and Mucosal Bicarbonate in Duodenal Neutralization of Acid in Anaesthetized Pigs. <i>Scandinavian Journal of Gastroenterology</i> , 1992, 27, 343-349.	1.5	11
78	Pancreatic, Hepatic, and Duodenal Mucosal Bicarbonate Secretion during Infusion of Secretin and Cholecystokinin: Evidence of the Importance of Hepatic Bicarbonate in the Neutralization of Acid in the Duodenum of Anaesthetized Pigs. <i>Scandinavian Journal of Gastroenterology</i> , 1991, 26, 1035-1041.	1.5	13
79	Duodenal Disappearance Rate of Acid during Inhibition of Mucosal Bicarbonate Secretion. <i>Digestion</i> , 1990, 47, 121-129.	2.3	9
80	Exogenous prostaglandins, alkaline secretion, and protection of duodenal mucosa. <i>Digestive Diseases and Sciences</i> , 1990, 35, 918-920.	2.3	0
81	Morphine Inhibits Secretion of Bicarbonate from the Human Duodenal Mucosa: Possible Role of Endogenous Opioids in the Regulation of Human Duodenal Mucosal Bicarbonate Secretion. <i>Scandinavian Journal of Gastroenterology</i> , 1990, 25, 1066-1075.	1.5	17
82	Intestinal Permeability of ⁵¹ Cr-labelled Ethylenediaminetetraacetic Acid in Patients with Crohn's Disease and Their Healthy Relatives. <i>Scandinavian Journal of Gastroenterology</i> , 1989, 24, 993-998.	1.5	75
83	Effects of Oleic Acid and Oleyl Alcohol on Cholecystokinin and Secretin in Plasma and Pancreatobiliary Secretion. <i>Scandinavian Journal of Gastroenterology</i> , 1989, 24, 529-532.	1.5	11
84	Is Extrapolation of Safety and Efficacy Data Possible?. <i>Frontiers of Gastrointestinal Research</i> , 0, , 107-112.	0.1	0